Androgen deprivation

DRUG4 trials

Sponsors

Centre Georges Francois Leclerc, Duke University, Andrew J. Armstrong, MD

Conditions

Prostate Cancer

Phase 2

Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer

TerminatedNCT01704027

Centre Georges Francois LeclercProstate Cancer

Start: 2012-10-31Updated: 2014-09-18

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

CompletedNCT01717053

Duke UniversityProstate Cancer

Start: 2014-01-17End: 2021-08-31Updated: 2022-10-10

Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)

CompletedNCT02057939

Duke UniversityProstate Cancer

Start: 2014-04-30End: 2019-06-05Updated: 2019-06-26

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

CompletedNCT03311555

Andrew J. Armstrong, MDProstate Cancer

Start: 2018-03-28End: 2022-12-22Updated: 2024-03-19

Related Papers

Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Journal of Clinical Oncology2023-06-011 citations

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Journal of Clinical Oncology2021-02-20

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

2020-02-1325 citations

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Journal of Clinical Oncology2019-05-201 citations

Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.

Journal of Clinical Oncology2019-03-012 citations

Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.

Journal of Clinical Oncology2018-02-204 citations